Comparing Metformin and Pioglitazone for Metabolic Syndrome Treatment
Author Information
Author(s): Mahajan Rajiv, Gupta Anita, Gupta Rajinder Singh, Gupta Kapil
Primary Institution: Adesh Institute of Medical Sciences and Research
Hypothesis
The study aims to evaluate the efficacy, safety, and cost-effectiveness of insulin sensitizers as add-on therapy in metabolic syndrome patients experiencing secondary sulfonylurea failure.
Conclusion
Metformin is more effective than pioglitazone in improving various health parameters in patients with metabolic syndrome and secondary sulfonylurea failure.
Supporting Evidence
- Metformin showed a significant reduction in body mass index compared to pioglitazone.
- Both therapies significantly reduced fasting blood glucose, glycosylated hemoglobin, and triglycerides.
- The cost-effectiveness ratio was more favorable for metformin compared to pioglitazone.
Takeaway
This study looked at two medicines, metformin and pioglitazone, to see which one helps people with a condition called metabolic syndrome better. It found that metformin works better.
Methodology
An open-label, prospective, randomized study was conducted on 200 patients with metabolic syndrome and secondary sulfonylurea failure, divided into two groups receiving either metformin or pioglitazone as add-on therapy.
Limitations
The study duration was limited to 24 weeks, and longer studies are needed to assess long-term effects.
Participant Demographics
Participants were adults aged 36 to 67 years, with a mean age of approximately 49 years.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website